Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
huNK2R(TACR2) Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

huNK2R(TACR2) Mouse

Product Name
huNK2R(TACR2) Mouse
Product ID
C002097
Strain Name
C57BL/6NCya-Tacr2tm1(hTACR2)/Cya
Backgroud
C57BL/6NCya
Status
Live Mouse
When using this mouse strain in a publication, please cite “huNK2R(TACR2) Mouse (Catalog C002097) were purchased from Cyagen.”
HUGO-GT Humanized ModelsMetabolic Target Humanized Mouse Models
Obesity and Diabetes Mellitus
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
HUGO-GT Humanized ModelsMetabolic Target Humanized Mouse Models
Obesity and Diabetes Mellitus

Basic Information

Related Resource

Basic Information
Gene Name
TACR2
Gene Alias
SKR, NK2R, NKNAR, TAC2R
NCBI ID
6865 (Human)
Chromosome
Chr 10 (Human)
MGI ID
MGI:98477
Datasheet
Click here to download >>

Strain Description

The TACR2 gene encodes tachykinin receptor 2 (also known as neurokinin 2 receptor, NK2R), a member of the G protein-coupled receptor (GPCR) superfamily that serves as a high-affinity receptor for neurokinin A (also referred to as substance K). Recent studies have shown that the TACR2/NK2R signaling pathway is closely associated with metabolic diseases such as obesity and type 2 diabetes (T2D) and plays important roles in regulating energy expenditure and appetite. NK2R agonists simultaneously promote energy expenditure and induce sustained non-aversive appetite suppression independently of the canonical leptin signaling pathway, thereby effectively reducing body weight and rapidly improving insulin sensitivity. In diet-induced obesity (DIO) mice, Ob/Ob mice, Mc4r knockout mice, and diabetic/obese cynomolgus monkey models, NK2R-selective agonists significantly reduced body weight, blood glucose, triglyceride, and cholesterol levels while improving insulin resistance, without causing any apparent severe adverse effects [1-2]. Therefore, as a single target capable of simultaneously regulating energy expenditure and appetite, NK2R represents a promising therapeutic target for metabolic diseases and provides a novel strategy for the development of precision therapies for obesity, type 2 diabetes (T2D), and related metabolic disorders.
The huNK2R(TACR2) humanized mouse was generated via gene-editing technology by replacing the sequence spanning from the start codon to the stop codon of the endogenous mouse Tacr2 gene with the corresponding sequence of the human TACR2 gene. Its primary applications include mechanistic studies of metabolic diseases such as obesity and type 2 diabetes (T2D), as well as the exploration of therapeutic strategies targeting the NK2R pathway. This model can also be used to evaluate the potential effects of related interventions on energy metabolism and appetite regulation.
Reference
Sass F, Ma T, Ekberg JH, Kirigiti M, Ureña MG, Dollet L, Brown JM, Basse AL, Yacawych WT, Burm HB, Andersen MK, Nielsen TS, Tomlinson AJ, Dmytiyeva O, Christensen DP, Bader L, Vo CT, Wang Y, Rausch DM, Kristensen CK, Gestal-Mato M, In Het Panhuis W, Sjøberg KA, Kernodle S, Petersen JE, Pavlovskyi A, Sandhu M, Moltke I, Jørgensen ME, Albrechtsen A, Grarup N, Babu MM, Rensen PCN, Kooijman S, Seeley RJ, Worthmann A, Heeren J, Pers TH, Hansen T, Gustafsson MBF, Tang-Christensen M, Kilpeläinen TO, Myers MG Jr, Kievit P, Schwartz TW, Hansen JB, Gerhart-Hines Z. NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature. 2024 Nov;635(8040):987-1000.
Pavlovskyi A, Ren Y, Gestal-Mato M, Olsen OH, Schwartz TW, Gerhart-Hines Z, Liu X. Structurally defining neurokinin selectivity to improve NK2R agonists. Nat Struct Mol Biol. 2026 Jul;33(7):1086-1096.

Strain Strategy

The mouse Tacr2 gene sequence from the start codon to the stop codon was replaced with the corresponding human TACR2 gene sequence.
Figure 1. Gene editing strategy of huNK2R(TACR2) mice.
Figure 1. Gene editing strategy of huNK2R(TACR2) mice.

Application Area

Mechanistic research on metabolic diseases, such as obesity and type 2 diabetes (T2D);
Therapeutic strategies targeting the NK2R pathway.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research